CASI Pharmaceuticals, Inc.
About
CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (AMR). The Phase 1 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with AMR.
US
601 Gateway Blvd, San Francisco, CA
94080
Public Company
41
Biotechnology Research
anti-CD38; immunology; AMR; ITP; autoimmune disease; organ transplant rejection
Top Decision Makers · 10
VP General Manager CASI Pharmaceutical Manufacturing Center
QIJUN ZHANG
China
******@***.com
Phone
(**) *** ****
Chief Medical Officer
Alex Zukiwski
United States
******@***.com
Phone
(**) *** ****
President
Larry Zhang
China
******@***.com
Phone
(**) *** ****
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.